Eli Lilly Receives FDA Approval for Onswik Diabetes Treatment

Key Facts

Eli Lilly received FDA approval for Onswik as a once-weekly basal insulin for adults with type 2 diabetes. Zacks reported that the injection is designed to provide a less frequent dosing alternative to daily injections, aiming to improve patient convenience and treatment adherence.

LLY closed at $1181.89 on September 24, 2026, with the stock reaching a day high of $1197.79. This regulatory milestone serves as a significant catalyst for the pharmaceutical firm within the diabetes care sector, following a session where the stock reached a low of $1151 on the same date.